<p>Aerovate Therapeutics, Inc.（纳斯达克代码：AVTE - 获取免费报告）在周一的期权交易中成为异常活跃的目标。投资者购买了 9,373 份该公司的看涨期权。这比典型的 392 份看涨期权的交易量增加了 2,291%。</p>
<p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金最近对该股票的持仓进行了调整。道富集团在第三季度将其在 Aerovate Therapeutics 的持股增加了 7.7%。道富集团目前拥有 367,468 股该公司的股票，价值 768,000 美元，此前在上个季度增持了 26,278 股。巴克莱银行在第三季度将其在 Aerovate Therapeutics 的股份提高了 310.8%。巴克莱银行目前拥有 18,972 股该公司的股票，价值 39,000 美元，此前在上个季度增持了 14,354 股。FNY 投资顾问公司在第四季度购买了 Aerovate Therapeutics 的新股份，价值 198,000 美元。Deltec 资产管理公司在第四季度购买了 Aerovate Therapeutics 的新股份，价值 514,000 美元。最后，Ieq Capital LLC 在第四季度获得了 Aerovate Therapeutics 的新持仓，价值约 38,000 美元。</p>
<h2>Aerovate Therapeutics 价格表现</h2>
<p>周一中午交易中，AVTE 的股价上涨了 0.01 美元，达到 2.69 美元。该公司交易了 586,168 股股票，而其平均交易量为 613,099 股。Aerovate Therapeutics 的 52 周低点为 1.25 美元，52 周高点为 25.29 美元。该公司的 50 日简单移动平均线为 2.53 美元，200 日简单移动平均线也为 2.53 美元。该股票的市值为 7782 万美元，市盈率为-0.90，贝塔值为 0.95。</p>
<p>Aerovate Therapeutics（纳斯达克代码：AVTE - 获取免费报告）最后一次发布财报是在 4 月 25 日，星期五。该公司报告本季度每股收益为（0.09 美元），超出市场共识预期的（0.30 美元）0.21 美元。股票研究分析师预测 Aerovate Therapeutics 在当前年度的每股收益将为-2.64 美元。</p>
<h2>Aerovate Therapeutics 股息公告</h2>
<p>该公司最近还宣布了一项股息，将于 4 月 28 日，星期一支付。4 月 25 日，星期五的股东将获得 2.40 美元的股息。该股息的除息日期为 4 月 29 日，星期二。</p>
<h2>Aerovate Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。它专注于推进 AV-101，这是一种干粉吸入剂型的伊马替尼，用于治疗肺动脉高压，目前处于 2b/3 期临床试验中。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Aerovate Therapeutics 更好</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>2025 年最佳防御类股票... 到目前为止</li>
<li>投资石油股票的方式和原因</li>
<li>字母表在强劲财报和回购公告后反弹</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克何时关闭</li>
<li>出售台积电会是巴菲特最大的遗憾吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aerovate Therapeutics 吗？</h2>
<p>在你考虑 Aerovate Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买... 而 Aerovate Therapeutics 并不在名单上。</p>
<p>虽然 Aerovate Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AVTE

<p>Aerovate Therapeutics, Inc.（纳斯达克代码：AVTE - 获取免费报告）在周一成为异常大量期权交易活动的目标。股票投资者购买了 9,373 份看涨期权。这比平均交易量 392 份看涨期权增加了约 2,291%</p>

<p>Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of unusually large options trading on Monday. Investors bought 9,373 call options on the company. This is an increase of 2,291% compared to the typical volume of 392 call options.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.（纳斯达克代码：AVTE - 获取免费报告）在周一的期权交易中成为异常活跃的目标。投资者购买了 9,373 份该公司的看涨期权。这比典型的 392 份看涨期权的交易量增加了 2,291%。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its position in shares of Aerovate Therapeutics by 7.7% during the 3rd quarter. State Street Corp now owns 367,468 shares of the company's stock valued at $768,000 after acquiring an additional 26,278 shares in the last quarter. Barclays PLC lifted its stake in Aerovate Therapeutics by 310.8% in the 3rd quarter. Barclays PLC now owns 18,972 shares of the company's stock valued at $39,000 after acquiring an additional 14,354 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in Aerovate Therapeutics during the fourth quarter worth $198,000. Deltec Asset Management LLC bought a new stake in Aerovate Therapeutics in the 4th quarter valued at $514,000. Finally, Ieq Capital LLC acquired a new position in shares of Aerovate Therapeutics in the fourth quarter valued at about $38,000.</p>
<div class="lb-trans"><p>一些对冲基金最近对该股票的持仓进行了调整。道富集团在第三季度将其在 Aerovate Therapeutics 的持股增加了 7.7%。道富集团目前拥有 367,468 股该公司的股票，价值 768,000 美元，此前在上个季度增持了 26,278 股。巴克莱银行在第三季度将其在 Aerovate Therapeutics 的股份提高了 310.8%。巴克莱银行目前拥有 18,972 股该公司的股票，价值 39,000 美元，此前在上个季度增持了 14,354 股。FNY 投资顾问公司在第四季度购买了 Aerovate Therapeutics 的新股份，价值 198,000 美元。Deltec 资产管理公司在第四季度购买了 Aerovate Therapeutics 的新股份，价值 514,000 美元。最后，Ieq Capital LLC 在第四季度获得了 Aerovate Therapeutics 的新持仓，价值约 38,000 美元。</p>
</div><h2>Aerovate Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 价格表现</h2>
</div><p>Shares of AVTE traded up $0.01 during mid-day trading on Monday, reaching $2.69. 586,168 shares of the company's stock were exchanged, compared to its average volume of 613,099. Aerovate Therapeutics has a 52-week low of $1.25 and a 52-week high of $25.29. The business's fifty day simple moving average is $2.53 and its 200-day simple moving average is $2.53. The stock has a market capitalization of $77.82 million, a PE ratio of -0.90 and a beta of 0.95.</p>
<div class="lb-trans"><p>周一中午交易中，AVTE 的股价上涨了 0.01 美元，达到 2.69 美元。该公司交易了 586,168 股股票，而其平均交易量为 613,099 股。Aerovate Therapeutics 的 52 周低点为 1.25 美元，52 周高点为 25.29 美元。该公司的 50 日简单移动平均线为 2.53 美元，200 日简单移动平均线也为 2.53 美元。该股票的市值为 7782 万美元，市盈率为-0.90，贝塔值为 0.95。</p>
</div><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its earnings results on Friday, April 25th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.21. Equities research analysts predict that Aerovate Therapeutics will post -2.64 earnings per share for the current year.</p>
<div class="lb-trans"><p>Aerovate Therapeutics（纳斯达克代码：AVTE - 获取免费报告）最后一次发布财报是在 4 月 25 日，星期五。该公司报告本季度每股收益为（0.09 美元），超出市场共识预期的（0.30 美元）0.21 美元。股票研究分析师预测 Aerovate Therapeutics 在当前年度的每股收益将为-2.64 美元。</p>
</div><h2>Aerovate Therapeutics Dividend Announcement</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 股息公告</h2>
</div><p>The business also recently announced a dividend, which will be paid on Monday, April 28th. Shareholders of record on Friday, April 25th will be given a $2.40 dividend. The ex-dividend date of this dividend is Tuesday, April 29th.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项股息，将于 4 月 28 日，星期一支付。4 月 25 日，星期五的股东将获得 2.40 美元的股息。该股息的除息日期为 4 月 29 日，星期二。</p>
</div><h2>Aerovate Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。它专注于推进 AV-101，这是一种干粉吸入剂型的伊马替尼，用于治疗肺动脉高压，目前处于 2b/3 期临床试验中。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Best Defense Stocks in 2025... So Far</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Alphabet Rebounds After Strong Earnings and Buyback Announcement</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Aerovate Therapeutics 更好</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>2025 年最佳防御类股票... 到目前为止</li>
<li>投资石油股票的方式和原因</li>
<li>字母表在强劲财报和回购公告后反弹</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克何时关闭</li>
<li>出售台积电会是巴菲特最大的遗憾吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aerovate Therapeutics 吗？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Aerovate Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买... 而 Aerovate Therapeutics 并不在名单上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aerovate Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

投资者大量买入 Aerovate Therapeutics（NASDAQ:AVTE）的看涨期权